Douglas Lane & Associates LLC Purchases 94,493 Shares of Zoetis Inc. $ZTS

Key Points

• Douglas Lane & Associates LLC boosted its Zoetis position by 30.8%, purchasing 94,493 shares in Q4 to own 401,246 shares worth about $50.49 million (roughly 0.09% of the company).
• Analyst coverage is mixed with a MarketBeat consensus of "Hold" and a consensus target price of $152.91 (six Buys, seven Holds, one Sell), though some firms have $160 targets.
• Zoetis recently beat quarterly EPS estimates ($1.48 vs. $1.40), set FY2026 guidance of 7.00–7.10 EPS, and pays a $0.53 quarterly dividend (annual $2.12; yield ~1.8%) while trading near $120 with a ~$50.7B market cap.

Douglas Lane & Associates LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 30.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 401,246 shares of the company's stock after buying an additional 94,493 shares during the period. Douglas Lane & Associates LLC owned 0.09% of Zoetis worth $50,485,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Willis Investment Counsel raised its position in shares of Zoetis by 40.1% in the 4th quarter. Willis Investment Counsel now owns 104,216 shares of the company's stock valued at $13,112,000 after purchasing an additional 29,806 shares during the last quarter. Personal CFO Solutions LLC increased its holdings in shares of Zoetis by 1.2% during the 4th quarter. Personal CFO Solutions LLC now owns 10,167 shares of the company's stock valued at $1,279,000 after purchasing an additional 123 shares in the last quarter. Banque de Luxembourg S.A. increased its holdings in shares of Zoetis by 754.0% during the 4th quarter. Banque de Luxembourg S.A. now owns 2,955 shares of the company's stock valued at $372,000 after purchasing an additional 2,609 shares in the last quarter. Flagship Harbor Advisors LLC increased its holdings in shares of Zoetis by 14.5% during the 4th quarter. Flagship Harbor Advisors LLC now owns 8,626 shares of the company's stock valued at $1,085,000 after purchasing an additional 1,094 shares in the last quarter. Finally, Quilter Plc grew its stake in Zoetis by 11.0% in the 4th quarter. Quilter Plc now owns 487,241 shares of the company's stock valued at $61,305,000 after acquiring an additional 48,282 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ZTS shares. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. Leerink Partners reiterated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. Bank of America boosted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a report on Friday, February 13th. Finally, BTIG Research reiterated a "buy" rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $152.91.

Zoetis Stock Up 0.2%

Shares of NYSE:ZTS opened at $120.01 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $50.66 billion, a PE ratio of 19.94, a price-to-earnings-growth ratio of 1.83 and a beta of 0.98. The firm's 50-day moving average is $122.36 and its two-hundred day moving average is $127.44. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the previous year, the company posted $1.40 earnings per share. The business's revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis's payout ratio is currently 35.22%.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Argus Research reiterated a Buy rating on Zoetis, signaling continued analyst confidence in growth prospects and likely supporting demand for the shares. Argus Research Remains a Buy on Zoetis (ZTS)
• Positive Sentiment: Zacks (picked up by MSN) profiles Zoetis as a top long-term value stock, pointing to attractive style scores and fundamentals that may draw value-oriented investors. Why Zoetis (ZTS) is a top value stock for the long term
• Positive Sentiment: Zacks notes Zoetis’ strong earnings-surprise history and says the stock has the key indicators that suggest another potential beat in the next quarterly report, which historically boosts short-term share performance around results. Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Coverage of Zoetis’ presentation at the World Vaccine Congress highlights deeper investment in biologics and vaccine R&D — a longer-term growth lever that can re-rate the stock if it leads to new products or market expansion. How Investors May Respond To Zoetis (ZTS) Deepening Its Biologics Focus After World Vaccine Congress Update
• Positive Sentiment: Earnings call transcripts reiterate diversified, franchise-level growth (companion animal and livestock), with Simparica Trio and other parasiticides driving strong unit/operational revenue gains — a fundamental support for recurring revenue growth. Zoetis (ZTS) Q2 2025 Earnings Call Transcript
• Neutral Sentiment: Brokerage consensus compiled by American Banking News shows a “Hold” rating on Zoetis, which tempers the unanimous bullish signal from some research shops and may limit upside from new positive headlines. Zoetis Inc. NYSE: ZTS Given Consensus Rating of "Hold" by Brokerages
• Neutral Sentiment: Some market pieces recommend tools (e.g., Zacks Earnings ESP) to identify potential earnings beats — useful for traders but not a direct company-specific catalyst. Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.